ArticleThe American journal of pathology2000

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

T A Järvinen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.